These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 1347154)

  • 1. Presynaptic effects of dopexamine hydrochloride in the canine kidney.
    Bass AS
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Jan; 345(1):33-6. PubMed ID: 1347154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting effects of dopexamine hydrochloride on electrolyte excretion in canine kidney.
    Bass AS
    J Pharmacol Exp Ther; 1990 May; 253(2):798-802. PubMed ID: 1971021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopexamine: a novel agonist at peripheral dopamine receptors and beta 2-adrenoceptors.
    Brown RA; Dixon J; Farmer JB; Hall JC; Humphries RG; Ince F; O'Connor SE; Simpson WT; Smith GW
    Br J Pharmacol; 1985 Jul; 85(3):599-608. PubMed ID: 2862944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cardiovascular actions of dopexamine hydrochloride, an agonist at dopamine receptors and beta 2-adrenoceptors in the dog.
    Smith GW; Hall JC; Farmer JB; Simpson WT
    J Pharm Pharmacol; 1987 Aug; 39(8):636-41. PubMed ID: 2888855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presynaptic dopamine receptors as mediators of dopamine-induced inhibition of neurogenic vasoconstriction.
    Lokhandwala MF; Buckley JP
    Eur J Pharmacol; 1977 Oct; 45(3):305-9. PubMed ID: 923639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal vasodilatation by dopexamine and fenoldopam due to alpha 1-adrenoceptor blockade.
    Martin SW; Broadley KJ
    Br J Pharmacol; 1995 May; 115(2):349-55. PubMed ID: 7670737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel orally active dopamine (DA) prodrug TA-870. IV. Renal vasodilatory and negative chronotropic effects in anesthetized dogs: influence of DA1 and DA2 dopamine receptor selective antagonists.
    Nishiyama S; Yoshikawa M; Yamaguchi I
    J Cardiovasc Pharmacol; 1991 Apr; 17(4):560-7. PubMed ID: 1711621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative significance of dopamine receptors, beta adrenoceptors and norepinephrine uptake inhibition in the cardiovascular actions of dopexamine hydrochloride.
    Goldberg LI; Bass AS
    Am J Cardiol; 1988 Aug; 62(5):37C-40C. PubMed ID: 2841837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dopexamine: a new dopaminergic agonist].
    Perrin G; Papazian L; Martin C
    Ann Fr Anesth Reanim; 1993; 12(3):308-20. PubMed ID: 7902685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390.
    Goldberg LI; Glock D; Kohli JD; Barnett A
    Hypertension; 1984; 6(2 Pt 2):I25-30. PubMed ID: 6144634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopexamine hydrochloride in the human kidney: localization, receptor binding and effect on 3'-5'-cyclic adenosine monophosphate generation.
    Napoleone P; Cavallotti C; Ricci A; Amenta F
    Nephron; 1993; 65(3):385-91. PubMed ID: 7904730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective DA2 versus DA1 antagonist activity of domperidone in the periphery.
    Kohli JD; Glock D; Goldberg LI
    Eur J Pharmacol; 1983 Apr; 89(1-2):137-41. PubMed ID: 6861882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anatomical localization of the binding and functional characterization of responses to dopexamine hydrochloride in the rat mesenteric vasculature.
    Amenta F; Ricci A; Napoleone P; Vyas SJ; Lokhandwala MF
    Pharmacology; 1991; 42(4):211-22. PubMed ID: 1677201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation by dopexamine of the cardiac responses to circulating and neuronally released norepinephrine: a possible mechanism for the therapeutic effects of the drug.
    Bass AS; Murphy MB; Kohli JD; Goldberg LI
    J Cardiovasc Pharmacol; 1989 Apr; 13(4):667-71. PubMed ID: 2471007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Uptake1 by dopexamine hydrochloride in vitro.
    Mitchell PD; Smith GW; Wells E; West PA
    Br J Pharmacol; 1987 Oct; 92(2):265-70. PubMed ID: 2890392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An introduction to the pharmacologic properties of Dopacard (dopexamine hydrochloride).
    Smith GW; O'Connor SE
    Am J Cardiol; 1988 Aug; 62(5):9C-17C. PubMed ID: 2900602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal effects of dopamine and dopexamine in the newborn anesthetized rabbit.
    Jaton T; Thonney M; Gouyon JB; Guignard JP
    Life Sci; 1992; 50(3):195-202. PubMed ID: 1346227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.
    Fitton A; Benfield P
    Drugs; 1990 Feb; 39(2):308-30. PubMed ID: 1970288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of dopexamine hydrochloride on contractions of rabbit isolated aorta evoked by various agonists.
    Nedergaard OA
    Pharmacol Toxicol; 1994 Jan; 74(1):43-9. PubMed ID: 7909151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical, autoradiographic and pharmacological evidence for the involvement of tubular DA-1 receptors in the natriuretic response to dopexamine hydrochloride.
    Vyas SJ; Apparsundaram S; Ricci A; Amenta F; Lokhandwala MF
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jan; 343(1):21-30. PubMed ID: 1674360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.